Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kyler Barkley

Cardiovascular Disease Lubbock, TX Medical Doctor

NPI 1144545781 CMS profile 1381335

3514 21St St, Lubbock, TX 79410

Open in the dashboard

General payments

$5,396

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyler Barkley of Lubbock, TX is reported in the CMS Open Payments database as having received $5,396 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,026 34
2024 General $707 27
2023 General $712 32
2022 General $805 36
2021 General $1,306 42
2020 General $147 10
2019 General $692 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyler Barkley
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Kyler Barkley were reported at $1,026. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Kyler Barkley Cardiovascular Disease median Middle half National median
2019 $692 $450 $127–$1,392 $163
2020 $147 $242 $77–$751 $114
2021 $1,306 $335 $101–$1,037 $132
2022 $805 $395 $121–$1,211 $149
2023 $712 $443 $136–$1,283 $160
2024 $707 $450 $136–$1,323 $164
2025 $1,026 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,077 35 payments
  2. Abiomed $563 9 payments
  3. Medtronic, Inc. $563 24 payments
  4. Novartis Pharmaceuticals Corporation $560 36 payments
  5. Shockwave Medical, Inc $431 6 payments
  6. Pfizer Inc. $402 29 payments
  7. Abbott Laboratories $327 4 payments
  8. AstraZeneca Pharmaceuticals LP $260 11 payments
  9. Medtronic Vascular, Inc. $171 12 payments
  10. E.R. Squibb & Sons, L.L.C. $171 12 payments
  11. Other $873 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,266 219 payments
  2. Education $131 3 payments
Products named General payments · program years 2019–2025
  1. Impella $542 8 payments
  2. ELIQUIS $386 28 payments
  3. ENTRESTO Cardiovascular $265 21 payments
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $225 4 payments
  5. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $207 2 payments
  6. ENTRESTO Cardiology/Vascular Diseases $186 9 payments
  7. SYMPLICITY G3 $186 1 payment
  8. ARTIX MT $161 7 payments
  9. Comet $143 1 payment
  10. BRILINTA $142 4 payments
  11. Other $3,059 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

11,426

Median for Cardiology: 2,533

Drug cost

$1,651,293

Median for Cardiology: $485,213

Branded share of claims

24.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 767 $799,175
Entresto Sacubitril/Valsartan Brand 234 $305,618
Xarelto Rivaroxaban Brand 150 $158,759
Repatha Sureclick Evolocumab Brand 117 $94,872
Farxiga Dapagliflozin Propanediol Brand 53 $65,372
Multaq Dronedarone Hcl Brand 33 $50,497
Praluent Pen Alirocumab Brand 39 $26,528
Metoprolol Succinate Generic 1,017 $14,382
Repatha Syringe Evolocumab Brand 14 $13,321
Ranolazine Er Ranolazine Brand 117 $11,394

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$276,312

Of which drugs: $326

Medicare patients

1,221

Average age 76

Services billed

4,315

593 women, 628 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 48%
Diabetes 34%
Chronic kidney disease 32%
Atrial fibrillation 31%
Heart failure 30%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 20 80 $326

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $109
$109 234 —
Wegovy
  • Novo Nordisk Inc $29
$29 — —
Ozempic
  • Novo Nordisk Inc $23
$23 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $17
$17 — —
ELIQUIS
  • PFIZER INC. $17
$17 767 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record